Cost-effectiveness of high-dose edoxaban compared to adjusted-dose warfarin for prevention of stroke and systemic embolism in non-valvular atrial fibrillation

被引：0
|
作者：
Mearns, E. [1 ]
Doleh, Y. [2 ]
Coleman, C. I. [1 ]
机构：
[1] Hartford Hosp, Hartford, CT 06115 USA
[2] Univ Connecticut, Storrs, CT USA
来源：
EUROPEAN HEART JOURNAL | 2014年 / 35卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
5110
引用
收藏
页码：896 / 896
页数：1
相关论文
共 50 条
  • [1] Cost-Effectiveness of High-Dose Edoxaban Compared with Adjusted-Dose Warfarin for Stroke Prevention in Non-Valvular Atrial Fibrillation Patients
    Nguyen, Elaine
    Egri, Florence
    Mearns, Elizabeth S.
    White, Charles M.
    Coleman, Craig I.
    PHARMACOTHERAPY, 2016, 36 (05): : 488 - 495
  • [2] Effect of renal function on the cost-effectiveness of high-dose edoxaban compared to adjusted-dose warfarin for stroke prevention in non-valvular atrial fibrillation patients
    Mearns, E. S.
    Coleman, C. I.
    EUROPEAN HEART JOURNAL, 2015, 36 : 1079 - 1079
  • [3] Cost-effectiveness of apixaban compared to edoxaban for stroke prevention in non-valvular atrial fibrillation
    Lip, G. Y. H.
    Kongnakorn, T.
    Lanitis, T.
    Phatak, H.
    Liu, J. X. C.
    Kuznik, A.
    Lawrence, J.
    Dorian, P.
    EUROPEAN HEART JOURNAL, 2014, 35 : 1108 - 1109
  • [4] Edoxaban versus warfarin for stroke prevention in non-valvular atrial fibrillation: a cost-effectiveness analysis
    Rognoni, Carla
    Marchetti, Monia
    Quaglini, Silvana
    Liberato, Nicola Lucio
    JOURNAL OF THROMBOSIS AND THROMBOLYSIS, 2015, 39 (02) : 149 - 154
  • [5] Edoxaban versus warfarin for stroke prevention in non-valvular atrial fibrillation: a cost-effectiveness analysis
    Carla Rognoni
    Monia Marchetti
    Silvana Quaglini
    Nicola Lucio Liberato
    Journal of Thrombosis and Thrombolysis, 2015, 39 : 149 - 154
  • [6] COST-EFFECTIVENESS ANALYSIS COMPARING DABIGATRAN AND ADJUSTED-DOSE WARFARIN FOR STROKE PREVENTION IN ATRIAL FIBRILLATION
    Zhao, Y.
    Lim, L.
    Coleman, C., I
    VALUE IN HEALTH, 2011, 14 (03) : A41 - A41
  • [7] COMPARATIVE EFFECTIVENESS OF EDOXABAN AND WARFARIN IN PREVENTION OF STROKE AND SYSTEMIC EMBOLISM IN NON-VALVULAR ATRIAL FIBRILLATION USING OBSERVATIONAL HEALTHCARE DATA
    Zhou, L.
    Zhang, R.
    Chakraborty, P.
    Farooq, F.
    Alford, Hensley S.
    VALUE IN HEALTH, 2018, 21 : S56 - S56
  • [8] COST-EFFECTIVENESS ANALYSIS OF APIXABAN VERSUS EDOXABAN FOR STROKE PREVENTION IN NON-VALVULAR ATRIAL FIBRILLATION PORTUGUESE PATIENTS
    de Andres-Nogales, F.
    Gay-Pobes, P. R.
    Ines, M.
    Polanco Sanchez, C.
    Alves, D.
    Oyaguez, I
    VALUE IN HEALTH, 2019, 22 : S549 - S550
  • [9] COST-EFFECTIVENESS ANALYSIS OF APIXABAN VERSUS EDOXABAN FOR STROKE PREVENTION IN NON-VALVULAR ATRIAL FIBRILLATION SPANISH PATIENTS
    de Andres-Nogales, F.
    Oyaguez, I
    Suarez, C.
    Lopez-Sendon, J. L.
    Gonzalez-Juanatey, J. R.
    Suarez, J.
    Polanco, C.
    VALUE IN HEALTH, 2018, 21 : S106 - S106
  • [10] Cost-effectiveness of Dabigatran for Stroke Prevention in Non-valvular Atrial Fibrillation in Spain
    Gonzalez-Juanatey, Jose R.
    Alvarez-Sabin, Jose
    Lobos, Jose M.
    Martinez-Rubio, Antoni
    Reverter, Joan C.
    Oyagueez, Itziar
    Gonzalez-Rojas, Nuria
    Becerra, Virginia
    REVISTA ESPANOLA DE CARDIOLOGIA, 2012, 65 (10): : 901 - 910
12345